• FDA cleared Pharming’s Joenja for APDS in children aged 4-11 weighing at least 27 kg, expanding the U.S. label.
• New 40 mg and 50 mg twice-daily doses are expected to reach the U.S. market in October.
• Joenja was previously authorized in the U.S. for APDS patients aged 12 and older.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609111400OMX_____CNEWS_EN_GNW1001262320_en) on September 11, 2026, and is solely responsible for the information contained therein.